3 results match your criteria: "Centre de Référence National des Maladies Rhumatologiques et Inflammatoires Pédiatriques (CERHUMIP)[Affiliation]"
Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units.
Rheumatology (Oxford)
October 2017
Service d'Immunologie, Hématologie et Rhumatologie Pédiatrique, Centre de Référence National des Maladies Rhumatologiques et Inflammatoires Pédiatriques (CERHUMIP), Hôpital Necker - Enfants Malades, AP-HP Paris.
[Prevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion].
Rev Med Interne
May 2016
Service de médecine interne 2, centre de référence national pour le lupus et le syndrome des antiphospholipides, institut E3M, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France.
Purpose: To develop French recommendations about the management of vaccinations, the screening of cervical cancer and the prevention of pneumocystis pneumonia in systemic lupus erythematosus (SLE).
Methods: Thirty-seven experts qualified in internal medicine, rheumatology, dermatology, nephrology and pediatrics have selected recommendations from a list of proposition based on available data from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified.
[Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion].
Rev Med Interne
June 2015
Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France.
Purpose: To develop French recommendations about screening and management of cardiovascular risk factors in systemic lupus erythematosus (SLE).
Methods: Thirty-nine experts qualified in internal medicine, rheumatology and nephrology have selected recommendations from a list developed based on evidence from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified.